The proposed developmental funds constitute an invaluable flexible funding source for the UCCC to pursue the initiatives and research opportunities identified though the planning and evaluation activities of the Cancer Center. The UCCC proposes to use these funds to 1) strengthen scientific programs, 2) support faculty recruitment in areas of strategic focus and need, 3) provide both junior and more established investigators the opportunity to explore research ideas of particular innovation and collaboration through pilot grant program funds, and 4) support the development of two new shared resources. Specifically, the UCCC proposes to allocate $200K per year in support of recruitment for seven faculty: Associate Director for Basic Science;senior breast and prostate cancer investigator;senior bladder cancer biologist;senior metastasis investigator and senior immunologist for the developing Metastasis and Tumor Microenvironment Program;and Program Co-leader for Cancer Cell Biology. An annual budget of $200K is proposed in support of the broad-based and diverse UCCC Pilot Grant Programs. A budget of $100K is proposed for each of two developing shared resources: 1) Preclinical Animal Services SR and 2) Human Research Imaging. Funding for these proposed projects totals $600K per year. For all categories of the request, the proposed funds will be supplemented to significant degrees by other institutional sources of funds. In summary, these funds provide a means to pursue the particulariy new and innovative initiatives, not generally funded by established sponsored research entities that potentiate Center-defining areas of scientific research.

Public Health Relevance

An NCl-designated Comprehensive Cancer Center, the UCCC is dedicated to the discovery of the nature of cancer and the development of more effective approaches to prevention, diagnosis and therapy. The requested Developmental funds provide flexibility to recruit faculty, fund pilot grants, and develop shared resources that strengthen the UCCC's research programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-25
Application #
8567538
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
25
Fiscal Year
2013
Total Cost
$280,873
Indirect Cost
$93,057
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Coleman, Carrie B; Lang, Julie; Sweet, Lydia A et al. (2018) Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice. J Virol 92:
Petersen, Dennis R; Orlicky, David J; Roede, James R et al. (2018) Aberrant expression of redox regulatory proteins in patients with concomitant primary Sclerosing cholangitis/inflammatory bowel disease. Exp Mol Pathol 105:32-36
Couts, Kasey L; Bemis, Judson; Turner, Jacqueline A et al. (2018) ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther 17:222-231
Nicholson, Andrew G; Torkko, Kathleen; Viola, Patrizia et al. (2018) Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. J Thorac Oncol 13:205-217
Greaves, Sarah A; Peterson, Jacob N; Torres, Raul M et al. (2018) Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance. Front Immunol 9:707
Thompson, Scott B; Wigton, Eric J; Krovi, Sai Harsha et al. (2018) The Formin mDia1 Regulates Acute Lymphoblastic Leukemia Engraftment, Migration, and Progression in vivo. Front Oncol 8:389
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Sang, Allison; Danhorn, Thomas; Peterson, Jacob N et al. (2018) Innate and adaptive signals enhance differentiation and expansion of dual-antibody autoreactive B cells in lupus. Nat Commun 9:3973
Ye, Haobin; Adane, Biniam; Khan, Nabilah et al. (2018) Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. Cancer Cell 34:659-673.e6
Flannery, Patrick C; DeSisto, John A; Amani, Vladimir et al. (2018) Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep 39:455-464

Showing the most recent 10 out of 1634 publications